WO2006123765A1 - Preparation recouverte d’un film - Google Patents

Preparation recouverte d’un film Download PDF

Info

Publication number
WO2006123765A1
WO2006123765A1 PCT/JP2006/309993 JP2006309993W WO2006123765A1 WO 2006123765 A1 WO2006123765 A1 WO 2006123765A1 JP 2006309993 W JP2006309993 W JP 2006309993W WO 2006123765 A1 WO2006123765 A1 WO 2006123765A1
Authority
WO
WIPO (PCT)
Prior art keywords
film
film coating
coating preparation
preparation according
film layer
Prior art date
Application number
PCT/JP2006/309993
Other languages
English (en)
Japanese (ja)
Inventor
Takeshi Hamaura
Susumu Hasegawa
Original Assignee
Daiichi Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Company, Limited filed Critical Daiichi Sankyo Company, Limited
Priority to JP2007516344A priority Critical patent/JP5000491B2/ja
Priority to CN2006800157266A priority patent/CN101171006B/zh
Priority to KR1020077026731A priority patent/KR101318032B1/ko
Publication of WO2006123765A1 publication Critical patent/WO2006123765A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a film coating preparation.
  • Patent Document 1 Japanese Patent Laid-Open No. 2003-300883
  • An object of the present invention is to provide a film coating preparation capable of reducing the odor of a drug.
  • the present inventors have surprisingly found that the odor of the formulation can be reduced by coating with a film layer containing sodium carboxymethyl cellulose, and the present invention has been completed. I let you.
  • the present invention provides:
  • Plasticizer strength Macrogol 6000 propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, phthalate, ethyl triethyl thiolate, lauric acid, sucrose, dextrose, sorbitol, triacetin, aceti (1) a film coating preparation according to (8), which is one or more compounds selected from noretretino recitrate, tritino recitrate, tributino recitrate, and acetiltyl butyl titrate;
  • the film coating preparation of the present invention contains sodium carboxymethyl cellulose (CMC-Na) in the film layer.
  • CMC-Na sodium carboxymethyl cellulose
  • the content of sodium carboxymethylcellulose in the film layer is not particularly limited as long as it can effectively reduce the odor of the drug, but usually the lower limit is 20% (w / w) or more. 30% (w / w) or more, more preferably 40% (w / w) or more, and the upper limit is 90% (w / w) or less, preferably 80% (w / w) ) Or less, more preferably 70% (w / w) or less.
  • coating bases or excipients can be blended as necessary.
  • the type of coating base or excipient is not particularly limited and can be appropriately selected by those skilled in the art. Can be selected.
  • Such coating bases or excipients include, for example, polyvinylbiridone (PVP), polyvinyl alcohol (PVA), methylcellulose, ethylcellulose, hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), dextrin, malto Mention may be made of dextrin, lactose, D-mannthol, polybutyl alcohol polymer, methacrylic acid copolymer, aminoalkyl methacrylate copolymer and ethyl acrylate 'methyl methacrylate copolymer.
  • PVP polyvinylbiridone
  • PVA polyvinyl alcohol
  • HPMC hydroxypropylmethylcellulose
  • dextrin malto Mention may be made of dextrin, lactose, D-mannthol,
  • the coating composition may be added with one or more additives such as plasticizers, excipients, lubricants, hiding agents, colorants, preservatives and the like in the usual amounts. Can be included.
  • additives such as plasticizers, excipients, lubricants, hiding agents, colorants, preservatives and the like in the usual amounts. Can be included.
  • plasticizer that can be used in the present invention is not particularly limited, and can be appropriately selected by those skilled in the art.
  • plasticizers include, for example, Macrogol 6000, propylene glycol, polyethylene glycol, polypropylene glycol, glycerin and sorbitol, glycerin triacetate, ethyl phthalate and triethyl taenoate, lauric acid, sucrose, dextrose, sonolebithonole, Examples include triacetin, acetinoretretinorecitrate, trietinoretrate, tributyltitrate, and acetitributylbutyrate.
  • excipients examples include lactose, mannitol, crystalline cellulose, dextrose, maltodextrin, and the like.
  • Examples of the lubricant that can be used in the present invention include talc, magnesium stearate, calcium stearate, and stearic acid.
  • Examples of the concealing agent that can be used in the present invention include titanium oxide.
  • Examples of the colorant that can be used in the present invention include titanium oxide, iron oxide, iron sesquioxide, yellow iron sesquioxide, yellow No. 5 aluminum lake talc and the like.
  • antiseptics examples include novene and the like.
  • the active ingredient contained in the film coating preparation is not limited by the structure, degree, etc. as long as it is a odorous drug, but preferably olmesartan medoxomil or 2-amino-5 -Isobutyl-4- ⁇ 2- [5- ( ⁇ , ⁇ '-bis ((S) -l-ethoxycarbol) ethyl) phosphonamide] fuller ⁇ thiazole, particularly preferably olmesartan Medoxomil. Olmesartan medoxomil is not suitable for hypertension or hypertension.
  • Blood pressure more specifically, hypertension, heart disease [angina, myocardial infarction, arrhythmia, heart failure or cardiac hypertrophy], kidney disease [diabetic nephropathy, glomerulonephritis or nephrosclerosis] Or cerebrovascular disease [cerebral infarction or cerebral hemorrhage]
  • 2-amino-5-isobutyl-4- ⁇ 2- [5- ( ⁇ , ⁇ '-bis ((S) -l-ethoxycarbol) ethyl) phosphonamide] fuller ⁇ thiazole is a diabetic It is effective for the prevention or treatment of hyperglycemia, glucose intolerance, obesity, diabetic complications, etc. (preferably prevention or treatment of diabetes), and easily according to the method described in WO 01Z47935 pamphlet etc. Can be manufactured.
  • the film coating preparation of the present invention may contain other effective components as necessary.
  • the active ingredient include diuretics such as Trichlor omethiazide, Hydrochlorothiazide ⁇ Benzylhydrochlorothiazide; Azelnidipine, Amlodipine ), Vedipine, -Trendepin, Manidipine, -Cardipine, Nifedipine, Sildidipine, Efonidipine, Calcium antagonists such as rudidipine (Barnidipine) and ferrodipine (Fel odipine); pioglitazone (Rosigl itazone), riboglitazone (Rivoglitazone), MCC-555, NN-2344, BMS-298585, AZ -242, LY-519818, insulin resistance improvers such as TAK-559; pravastatin, simvastatin, atorvastatin HMG-CoA reductase inhibitors such as (A)
  • Examples of the film coating preparation in the present invention include tablets, capsules, powders, fine granules, granules, troches and the like, and tablets are preferred.
  • the film coating preparation prepared by this method is obtained by spraying a film coating solution containing carboxymethyl cellulose sodium as a coating base onto an object to be coated such as a tablet or drug substance. Can do.
  • the object to be coated may be sub-coated if desired.
  • the film coating solution is obtained by suspending and dissolving sodium carboxymethylcellulose and the above-mentioned additive blended if necessary in water.
  • the spraying of the film coating solution may be performed by a known method such as using a commercially available film coating machine. These production conditions may be the same as those used in the production of ordinary film coating preparations.
  • the amount of the film coating is not particularly limited as long as it is an amount that can effectively reduce the odor of the drug, but usually the lower limit is 1% (w / w) or more with respect to the prescription weight, preferably 3% (w / w) or more, more preferably 6% (w / w) or more, and the upper limit is 50% (w / w) or less, preferably 20% (w / w) or less, based on the prescription weight, More preferably, the concentration is 10% (w / w) or less.
  • the thickness of the film layer is not particularly limited as long as it can effectively reduce the odor of the drug, but the lower limit is usually 1 m or more, preferably 5 m or more, more preferably 10 m or more. Particularly preferably, it is 20 ⁇ m or more, and the upper limit is 1000 ⁇ m or less, preferably 500 ⁇ m or less, more preferably 200 ⁇ m or less, and particularly preferably 100 ⁇ m or less.
  • the film thickness of the film layer can be measured with an ultra-deep color 3D shape measuring microscope VK-9500 (Keyence Co., Ltd.).
  • the film coating preparation of the present invention obtained by caulking may be administered in the same manner as a normal preparation.
  • Olmesartan medoxomil 300g, lactose 1850g, hydroxypropylmethylcellulose 60g, croscarmellose sodium 175g are mixed with a high-speed stirring granulator (VG-10, Baurec), granulated with 500g of purified water, and fluidized bed dryer (Baurec).
  • the granulated product was sized with a sizing machine (Comil, Norrec) and mixed with 15 g of magnesium stearate in a mixer (V-type mixer, Tokuju Seisakusho).
  • Tablets and uncoated tablets were obtained with a rotary tableting machine (Kikusui Seisakusho) using a mortar with a diameter of 7 mm and an R face with a curvature radius of 8 mm so that the weight of each tablet was 160 mg.
  • a coating solution in which hydroxypropylmethylcellulose 140 g, talc 30 g, and titanium oxide 30 g are suspended in 1800 g of purified water, 1000 g of the uncoated tablet obtained in Example 1, a coating machine (Driacoater DRC-300, Norec) is used.
  • the film-coated tablet (B) was obtained by coating 6% (w / w) with respect to the uncoated tablet weight.
  • the uncoated tablet and film-coated tablet (A) produced in Example 1 and 30 film-coated tablets (B) produced in Comparative Example 1 were placed in a glass bottle and stored at 40 ° C. for 3 hours. The glass bottle was opened, and five subjects performed a sensory test of odor according to the following evaluation criteria. The results are shown in Table 1.
  • Example 2 Using the coating solution obtained by suspending 140 g of hydroxypropylmethylcellulose, 30 g of talc, and 30 g of titanium oxide in 1800 g of purified water to the plain tablet lOOOOg obtained in Example 1, it was applied to a coating machine (Driacoater DRC-300, Palek). Then, 6% (w / w) coating was performed on the weight of the uncoated tablet to obtain a film-coated tablet (D).
  • a coating machine Driacoater DRC-300, Palek
  • Example 2 In a glass bottle, the uncoated tablet produced in Example 1 and the film-coated tablet produced in Example 2 ( C), film-coated tablets produced in Comparative Example 2 (D) 30 tablets each, 40 Stored at C for 3 hours. The glass bottle was opened, and the odor sensory test was conducted by the five subjects according to the following evaluation criteria. The results are shown in Table 2.

Abstract

La présente invention concerne une préparation recouverte d’un film qui contient un médicament odorant dans sa formulation et contient également du carboxyméthylcellulose sodique dans sa couche de film.
PCT/JP2006/309993 2005-05-20 2006-05-19 Preparation recouverte d’un film WO2006123765A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007516344A JP5000491B2 (ja) 2005-05-20 2006-05-19 フィルムコーティング製剤
CN2006800157266A CN101171006B (zh) 2005-05-20 2006-05-19 薄膜包衣制剂
KR1020077026731A KR101318032B1 (ko) 2005-05-20 2006-05-19 필름 코팅 제제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005147436 2005-05-20
JP2005-147436 2005-05-20

Publications (1)

Publication Number Publication Date
WO2006123765A1 true WO2006123765A1 (fr) 2006-11-23

Family

ID=37431333

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/309993 WO2006123765A1 (fr) 2005-05-20 2006-05-19 Preparation recouverte d’un film

Country Status (5)

Country Link
JP (1) JP5000491B2 (fr)
KR (1) KR101318032B1 (fr)
CN (1) CN101171006B (fr)
TW (1) TWI367755B (fr)
WO (1) WO2006123765A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008050714A1 (fr) * 2006-10-25 2008-05-02 Daiichi Sankyo Company, Limited Matériel de conditionnement
WO2008078728A1 (fr) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Composition pharmaceutique contenant de l'acide ascorbique
WO2008078727A1 (fr) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Composition pharmaceutique à capacité de dissolution améliorée
WO2009057569A1 (fr) * 2007-10-29 2009-05-07 Daiichi Sankyo Company, Limited Préparation pelliculée
WO2010018777A1 (fr) * 2008-08-11 2010-02-18 第一三共株式会社 Procédé de lutte contre les mauvaises odeurs
JPWO2008069262A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
CN102028663A (zh) * 2010-12-14 2011-04-27 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
JP2011195567A (ja) * 2010-02-26 2011-10-06 Daiichi Sankyo Co Ltd 錠剤
WO2012029820A1 (fr) 2010-08-31 2012-03-08 東レ株式会社 Agent de revêtement pour préparation solide pharmaceutique, formulation de film pharmaceutique, et préparation solide pharmaceutique revêtue
JP2014517046A (ja) * 2011-06-24 2014-07-17 アセンダ ファーマ インコーポレイテッド エステルプロドラッグの吸収を改善するための方法及び改善された医薬組成物
WO2014188728A1 (fr) * 2013-05-24 2014-11-27 持田製薬株式会社 Composition pour enrobage par film
JP2016044170A (ja) * 2014-08-27 2016-04-04 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
JP2017001999A (ja) * 2015-06-12 2017-01-05 富士フイルム株式会社 薬物含有粒子の製造方法、薬物含有粒子、医薬組成物、及び口腔内崩壊錠
WO2017164208A1 (fr) * 2016-03-24 2017-09-28 第一三共株式会社 Médicament pour le traitement d'une maladie rénale
CN114522146A (zh) * 2022-01-21 2022-05-24 上海睿奕生物科技有限公司 白色无钛薄膜包衣材料及其制备方法和制备应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI461215B (zh) * 2011-06-24 2014-11-21 Acenda Pharma Inc 用以改善酯類前驅藥吸收率的方法與改良之藥學組合物
KR102103530B1 (ko) * 2018-06-29 2020-04-22 주식회사 코피텍 필름 코팅용 조성물 및 이를 코팅한 정제

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003051973A (ja) * 2001-08-07 2003-02-21 Hitachi Maxell Ltd カメラモジュール
JP2003048852A (ja) * 2000-11-21 2003-02-21 Sankyo Co Ltd 医薬組成物
WO2004067003A1 (fr) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
JP2005162619A (ja) * 2003-11-28 2005-06-23 Ss Pharmaceut Co Ltd 揮散防止型固形製剤およびその製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
EP1058543A1 (fr) * 1998-12-31 2000-12-13 Hercules Incorporated Compositions d'hydroxypropylcellulose et de polymere anionique et leur emploi comme enrobage par film pour produits pharmaceutiques
MXPA02006156A (es) * 1999-12-22 2003-09-22 Metabasis Therapeutics Inc Nuevos profarmacos de bisamidato fosfonato.
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
DK1336407T3 (da) * 2000-11-21 2006-09-04 Sankyo Co Præparat indeholdende en angiotensin-II-receptorantagonist og et diuretikum og anvendelse deraf til behandling af hypertension

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003048852A (ja) * 2000-11-21 2003-02-21 Sankyo Co Ltd 医薬組成物
JP2003051973A (ja) * 2001-08-07 2003-02-21 Hitachi Maxell Ltd カメラモジュール
WO2004067003A1 (fr) * 2003-01-31 2004-08-12 Sankyo Company, Limited Medicament pour la prevention et le traitement de l'arteriosclerose et de l'hypertension
JP2005162619A (ja) * 2003-11-28 2005-06-23 Ss Pharmaceut Co Ltd 揮散防止型固形製剤およびその製造方法

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008050714A1 (fr) * 2006-10-25 2008-05-02 Daiichi Sankyo Company, Limited Matériel de conditionnement
JPWO2008069262A1 (ja) * 2006-12-07 2010-03-25 第一三共株式会社 安定性が改善されたフィルムコーティング製剤
JP5241511B2 (ja) * 2006-12-26 2013-07-17 第一三共株式会社 溶出性の改善された医薬組成物
WO2008078727A1 (fr) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Composition pharmaceutique à capacité de dissolution améliorée
WO2008078728A1 (fr) * 2006-12-26 2008-07-03 Daiichi Sankyo Company, Limited Composition pharmaceutique contenant de l'acide ascorbique
TWI414310B (zh) * 2006-12-26 2013-11-11 Daiichi Sankyo Co Ltd 溶出性改善之醫藥品組成物
WO2009057569A1 (fr) * 2007-10-29 2009-05-07 Daiichi Sankyo Company, Limited Préparation pelliculée
JPWO2009057569A1 (ja) * 2007-10-29 2011-03-10 第一三共株式会社 フィルムコーティング製剤
WO2010018777A1 (fr) * 2008-08-11 2010-02-18 第一三共株式会社 Procédé de lutte contre les mauvaises odeurs
JP5688799B2 (ja) * 2008-08-11 2015-03-25 第一三共株式会社 におい抑制方法
JP2015017136A (ja) * 2008-08-11 2015-01-29 第一三共株式会社 におい抑制方法
JP2011195567A (ja) * 2010-02-26 2011-10-06 Daiichi Sankyo Co Ltd 錠剤
WO2012029820A1 (fr) 2010-08-31 2012-03-08 東レ株式会社 Agent de revêtement pour préparation solide pharmaceutique, formulation de film pharmaceutique, et préparation solide pharmaceutique revêtue
US9381248B2 (en) 2010-08-31 2016-07-05 Toray Industries, Inc. Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation
CN102028663A (zh) * 2010-12-14 2011-04-27 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
JP2014517046A (ja) * 2011-06-24 2014-07-17 アセンダ ファーマ インコーポレイテッド エステルプロドラッグの吸収を改善するための方法及び改善された医薬組成物
WO2014188728A1 (fr) * 2013-05-24 2014-11-27 持田製薬株式会社 Composition pour enrobage par film
JPWO2014188728A1 (ja) * 2013-05-24 2017-02-23 持田製薬株式会社 フィルムコーティング用組成物
JP2016044170A (ja) * 2014-08-27 2016-04-04 日本ケミファ株式会社 オルメサルタンのプロドラッグ製剤
JP2017001999A (ja) * 2015-06-12 2017-01-05 富士フイルム株式会社 薬物含有粒子の製造方法、薬物含有粒子、医薬組成物、及び口腔内崩壊錠
WO2017164208A1 (fr) * 2016-03-24 2017-09-28 第一三共株式会社 Médicament pour le traitement d'une maladie rénale
CN108778334A (zh) * 2016-03-24 2018-11-09 第三共株式会社 用于治疗肾脏疾病的药物
CN114522146A (zh) * 2022-01-21 2022-05-24 上海睿奕生物科技有限公司 白色无钛薄膜包衣材料及其制备方法和制备应用

Also Published As

Publication number Publication date
JPWO2006123765A1 (ja) 2008-12-25
CN101171006B (zh) 2010-12-01
TW200719891A (en) 2007-06-01
CN101171006A (zh) 2008-04-30
TWI367755B (en) 2012-07-11
KR101318032B1 (ko) 2013-10-14
JP5000491B2 (ja) 2012-08-15
KR20080011394A (ko) 2008-02-04

Similar Documents

Publication Publication Date Title
WO2006123765A1 (fr) Preparation recouverte d’un film
JP4979577B2 (ja) デキストロース含有フィルムコーティング製剤
JPWO2009057569A1 (ja) フィルムコーティング製剤
JP5854571B2 (ja) におい抑制方法
CA2874779C (fr) Composition pharmaceutique d'entecavir, et procede de fabrication
JP6166781B2 (ja) ５−クロロ−ｎ−（｛（５ｓ）−２−オキソ−３−［４−（３−オキソ−４−モルホリニル）フェニル］−１，３−オキサゾリジン−５−イル｝メチル）−２−チオフェンカルボキサミドを含む医薬投与形態
AU2016361612B2 (en) Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine
JP2015061828A (ja) 口腔内崩壊錠及びその製造方法
JP5764070B2 (ja) アトルバスタチン含有被覆製剤
RU2414903C1 (ru) Фармацевтический состав пролонгированного действия на основе клозапина перорального введения
WO2009027786A2 (fr) Formes posologiques matricielles de varénicline
JP6854384B2 (ja) 医薬組成物
EP3334419A1 (fr) Composition pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz
KR20190038283A (ko) 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
JP2019526641A (ja) テソフェンシン組成物
HUE027829T2 (en) Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
WO2024084496A1 (fr) Compositions pharmaceutiques comprenant du maléate d'acalabrutinib
TWI484955B (zh) 治療包括人類之哺乳動物中第２型糖尿病的醫藥組成物
CN101590236A (zh) 含有钙拮抗剂、他汀类药物的组合物及其用途

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680015726.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007516344

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020077026731

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06746649

Country of ref document: EP

Kind code of ref document: A1